Condition category
Urological and Genital Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Haemodialysis (HD) is a life-saving and life-sustaining treatment. Effective HD requires a reliable, long-term and safe vascular access (approach into the blood stream). Native AV fistulae (AVFs) are the preferred vascular access for their low complication rates and longevity. However, AVFs have high early failure rates, but once matured they have a relatively longer operational life and a lower complication rate, especially from infections, when compared to prosthetic grafts (AVGs) and dialysis catheters. This study aims to understand the natural history of AVF maturation and identify factors influencing outcomes.

Who can participate?
Patients in need of upper limb AVF for haemodialysis

What does the study involve?
The patient attends three extra scans. Blood samples are taken and the patient is followed up over a monthly basis for a year. They may have two additional visits to the hospital.

What are the possible benefits and risks of participating?
Participants receive two additional scans and are closely monitored. Participants may need to have extra needles inserted for research blood tests, although every effort will be made to take them at the scheduled blood tests, thus further reducing the small risks associated with taking blood from the veins.

Where is the study run from?
Central Manchester University Hospitals NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?
October 2011 to March 2022

Who is funding the study?
Bioconnect Systems Inc. (USA)

Who is the main contact?
Miss Carla Barrett

Trial website

Contact information



Primary contact

Miss Carla Barrett


Contact details

Manchester Royal Infirmary
Oxford Road
M13 9WL
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Understanding haemodialysis vascular access maturation: a prospective observational study to understand the natural history and biology of AV access maturation and identify risk factors for AVF failure



Study hypothesis

To understand the natural history of AVF maturation and identify factors influencing outcomes.

Ethics approval

NRES Committee North West –Preston, 17/02/2011, ref. 11/H1016/3

Study design

Randomised; Interventional; Design type: Not specified, Screening

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please contact to request a patient information sheet


Topic: Renal disorders; Subtopic: Renal disorders; Disease: All Renal disorders


Extra bloods at baseline: Patients will have an extra blood test at this point for haematological/biochemical parameters and DNA/stem cell sampling and analysis. Extra blood tests will be optional and will not be mandatory for all participating centres. Perioperatively - blood tests, patients will undergo further blood tests peri-operatively and these will be linked to their peri-operative clinically indicated blood tests; blood tests will be optional and are not mandatory for study inclusion. US scan - follow-up, Doppler ultrasound scan will be used to assess maturation.

It is anticipated that most patients will have two extra visits with tests during their visits (routine postoperative visit and scan at 6 weeks is standard clinical practice). For the minority of patients who have not used their fistula by 6 months, we will perform the final study evaluation with US at 6 months.

Intervention type



Not Applicable

Drug names

Primary outcome measure

Successful (unassisted) maturation defined as either A or B
A: Use of the AVF with two needles

Secondary outcome measures

Not provided at time of registration

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. The participant is in need of AV dialysis access for haemodialysis.
2. Participant is available and can return for follow-up visits
Target Gender: Male & Female ; Lower Age Limit 18 years

Participant type


Age group




Target number of participants

Planned Sample Size: 250; UK Sample Size: 250

Participant exclusion criteria

Inability to give consent and comply with the study follow-up schedule

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Manchester Royal Infirmary
M13 9WL
United Kingdom

Sponsor information


Central Manchester & Manchester Childrens University Hospital NHS Trust (UK)

Sponsor details

Department of Gastroenterology
Manchester Royal Infirmary
Oxford Road
M13 9PL
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Bioconnect Systems Inc. (USA)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

2014 thesis in (added 01/09/2020)

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

24/09/2020: The overall trial end date has been changed from 30/06/2015 to 01/03/2022 and the plain English summary has been updated accordingly. 01/09/2020: Added link to thesis. 10/08/2017: No publications found, verifying study status with principal investigator.